Wildcat Capital Management’s UroGen Pharma URGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-495,606
| Closed | -$6.79M | – | 6 |
|
|
2025
Q2 | $6.79M | Hold |
495,606
| – | – | 4.03% | 4 |
|
|
2025
Q1 | $5.48M | Hold |
495,606
| – | – | 2.93% | 4 |
|
|
2024
Q4 | $5.28M | Hold |
495,606
| – | – | 2.09% | 4 |
|
|
2024
Q3 | $6.29M | Hold |
495,606
| – | – | 3.08% | 4 |
|
|
2024
Q2 | $8.32M | Hold |
495,606
| – | – | 2.04% | 9 |
|
|
2024
Q1 | $7.43M | Hold |
495,606
| – | – | 2.7% | 10 |
|
|
2023
Q4 | $7.43M | Hold |
495,606
| – | – | 2.57% | 11 |
|
|
2023
Q3 | $6.94M | Hold |
495,606
| – | – | 2.79% | 11 |
|
|
2023
Q2 | $5.13M | Hold |
495,606
| – | – | 1.95% | 14 |
|
|
2023
Q1 | $4.58M | Sell |
495,606
-37,533
| -7% | -$345K | 1.7% | 15 |
|
|
2022
Q4 | $4.73M | Hold |
533,139
| – | – | 1.81% | 15 |
|
|
2022
Q3 | $4.44M | Hold |
533,139
| – | – | 1.7% | 17 |
|
|
2022
Q2 | $4.37M | Hold |
533,139
| – | – | 1.45% | 17 |
|
|
2022
Q1 | $4.64M | Hold |
533,139
| – | – | 1.19% | 16 |
|
|
2021
Q4 | $5.07M | Hold |
533,139
| – | – | 0.83% | 15 |
|
|
2021
Q3 | $8.97M | Hold |
533,139
| – | – | 1.16% | 18 |
|
|
2021
Q2 | $8.14M | Hold |
533,139
| – | – | 0.92% | 15 |
|
|
2021
Q1 | $10.4M | Sell |
533,139
-719,146
| -57% | -$15.3M | 1.27% | 14 |
|
|
2020
Q4 | $22.6M | Hold |
1,252,285
| – | – | 2.84% | 9 |
|
|
2020
Q3 | $24.2M | Buy |
1,252,285
+352,137
| +39% | +$7.97M | 7.72% | 5 |
|
|
2020
Q2 | $23.5M | Hold |
900,148
| – | – | 8.12% | 4 |
|
|
2020
Q1 | $16.1M | Sell |
900,148
-255,714
| -22% | -$6.91M | 7.31% | 5 |
|
|
2019
Q4 | $38.6M | Buy |
1,155,862
+99,800
| +9% | +$2.72M | 11.13% | 3 |
|
|
2019
Q3 | $25.2M | Buy |
1,056,062
+212,697
| +25% | +$6.95M | 10.69% | 2 |
|
|
2019
Q2 | $30.3M | Buy |
843,365
+64,362
| +8% | +$2.37M | 13.12% | 2 |
|
|
2019
Q1 | $28.8M | Buy |
779,003
+166,509
| +27% | +$6.98M | 16.87% | 2 |
|
|
2018
Q4 | $26.4M | Buy |
612,494
+237,015
| +63% | +$10.7M | 17.34% | 2 |
|
|
2018
Q3 | $17.7M | Buy |
375,479
+124,020
| +49% | +$5.76M | 13.68% | 2 |
|
|
2018
Q2 | $12.5M | Buy |
251,459
+69,757
| +38% | +$4.06M | 9.57% | 4 |
|
|
2018
Q1 | $9.03M | Buy |
181,702
+54,389
| +43% | +$2.72M | 7.45% | 4 |
|
|
2017
Q4 | $4.74M | Sell |
127,313
-7,687
| -6% | -$274K | 5.04% | 5 |
|
|
2017
Q3 | $4.25M | Hold |
135,000
| – | – | 0.76% | 10 |
|
|
2017
Q2 | $2.44M | Buy |
+135,000
| New | +$2.34M | 0.65% | 13 |
|
Other funds holding URGN
RI
PBA
JFG
SCM
ACA
Wildcat Capital Management's URGN Position: Q3 2025 in Review
Wildcat Capital Management sold out of UroGen Pharma (URGN) in Q3 2025, closing a stake of 495,606 shares — an estimated $6.79M sold.
Wildcat Capital Management first reported a position in URGN in Q2 2017 and held it in 33 quarters. The position peaked at $38.6M in Q4 2019. 161 funds tracked by Wall St. Rank hold URGN as of Q3 2025.
- Wildcat Capital Management reported no remaining UroGen Pharma position as of Q3 2025 after selling out during the quarter.
- Wildcat Capital Management sold 495,606 UroGen Pharma shares in Q3 2025, an estimated $6.79M.
- Wildcat Capital Management first reported a position in UroGen Pharma in Q2 2017 and held it in 33 quarters.
- Wildcat Capital Management's UroGen Pharma position peaked at $38.6M in Q4 2019.
- 161 funds tracked by Wall St. Rank held UroGen Pharma as of Q3 2025.
Based on Wildcat Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.